Tandem Diabetes Care, Inc. (TNDM) News
Follow Tandem Diabetes Care, Inc. (TNDM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Tandem Diabetes Care Reports Quarterly Results
The report covers the quarter ended September 30. The supplied text contains no results figures.
EQUITY | Nov 06, 2026, 12:57 AM UTC
L
Tandem Diabetes Shares Rise on Higher Sales, New CEO
By Katherine HamiltonTandem Diabetes shares rose after it logged higher sales and named a new chief executive.The stock gained 8% to $19.50 in after-hours trading after closing down 6%.The diabetes technology company app
EQUITY | Nov 05, 2026, 10:33 PM UTC
M
Tandem Diabetes Q3 Sales Rise on International Growth; Reaffirms 2026 Outlook
EARNINGS | Nov 05, 2026, 09:49 PM UTC
L
Tandem Diabetes Care: Bankes Will Succeed John Sheridan, Who Will Retire at End of 2026 >TNDM
Tandem Diabetes Care: Bankes Will Succeed John Sheridan, Who Will Retire at End of 2026 >TNDM
EQUITY | Nov 05, 2026, 09:38 PM UTC
L
Tandem Diabetes Care 3Q Sales $191M >TNDM
Tandem Diabetes Care 3Q Sales $191M >TNDM
EQUITY | Nov 05, 2026, 09:25 PM UTC
M
Tandem Diabetes Care Sees 2026 International Sales of $335M-$340M
Tandem Diabetes Care expects international sales of approximately $335 million to $340 million in 2026.
EARNINGS | Nov 05, 2026, 09:17 PM UTC
M
Tandem Diabetes Care Sees 2026 U.S. Sales of $730M-$745M
EARNINGS | Nov 05, 2026, 09:17 PM UTC
L
Tandem Diabetes Care Backs 2026 Sales $1.065B-$1.085B >TNDM
Tandem Diabetes Care Backs 2026 Sales $1.065B-$1.085B >TNDM
EARNINGS | Nov 05, 2026, 09:17 PM UTC
L
Tandem Diabetes Care 3Q Loss/Shr 10c >TNDM
Tandem Diabetes Care 3Q Loss/Shr 10c >TNDM
EQUITY | Nov 05, 2026, 09:05 PM UTC
H
Tandem Diabetes Care Q2 2026 Earnings Call Transcript
Tandem Diabetes Care (NASDAQ: TNDM ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to
LIVE | Oct 12, 2026, 10:24 AM UTC
L
Tandem Diabetes Care Is Maintained at Buy by Truist Securities
Ratings actions from Benzinga: GMT) Tandem Diabetes Care Price Target Cut to $28.00/Share From $31.00 by Truist SecuritiesRatings actions from Benzinga
NEWS | Sep 24, 2026, 04:17 PM UTC
L
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughl
REGULATION | Sep 23, 2026, 08:42 PM UTC
M
Tandem Diabetes upgrades to Outperform at WBLR
TNDM is marked new Outperform at WBLR, with no catalyst, price target, or additional details supplied in the alert.
EQUITY | Aug 21, 2026, 12:33 PM UTC
L
TNDM initiated Outperform at William Blair
William Blair initiated coverage of TNDM with an Outperform rating, according to Hammerstone MarketTalk; no additional price target or catalyst was provided.
EQUITY | Aug 21, 2026, 11:58 AM UTC
H
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ: AIRS ) fell sharply in pre-market trading following second-quarter results. Ai
EARNINGS | Aug 10, 2026, 12:02 PM UTC
L
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est
Tandem Diabetes Care (NASDAQ: TNDM ) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.
EARNINGS | Aug 06, 2026, 08:23 PM UTC
H
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: UBS upgraded Intuitive Surgical (I
EARNINGS | Jul 28, 2026, 01:35 PM UTC
L
BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate
BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate MMED @ UBS
EQUITY | Jul 28, 2026, 11:50 AM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC